Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients by Wanchu, A et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Infectious Diseases
BMC Infectious Diseases  2002,  2 x Research article
Antitubercular therapy decreases nitric oxide production in 
HIV/TB coinfected patients
AW a n c h u * 1, A Bhatnagar2, M Khullar2, A Sud1, P Bambery1 and S Singh1
Address: 1Department of Internal Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, INDIA and 2Department of 
Experimental Medicine and Biotechnology, Post-Graduate Institute of Medical Education and Research, Chandigarh, INDIA
E-mail: A Wanchu* - awanchu@glide.net.in; A Bhatnagar - abhat19@yahoo.co.in; M Khullar - madhukhu@yahoo.com; 
A Sud - asud@icpmr.wsahs.nsw.gov.au; P Bambery - pradeepbambery@hotmail.com; S Singh - surjit51@hotmail.com
*Corresponding author
Abstract
Background:  Nitric oxide (NO) production is increased among patients with human
immunodeficiency virus (HIV) infection and also among those with tuberculosis (TB). In this study
we sought to determine if there was increased NO production among patients with HIV/TB
coinfection and the effect of four weeks chemotherapy on this level.
Methods: 19 patients with HIV/TB coinfection were studied. They were treated with standard
four drug antitubercular therapy and sampled at baseline and four weeks. 20 patients with HIV
infection, but no opportunistic infections, were disease controls and 20 individuals were healthy
controls. Nitrite and citrulline, surrogate markers for NO, were measured spectrophotometrically.
Results: The mean age of HIV/TB patients was 28.4 ± 6.8 years and CD4 count was 116 ± 36.6/
mm. Mean nitrite level among HIV/TB coinfected was 207.6 ± 48.8 nmol/ml. This was significantly
higher than 99.7 ± 26.5 nmol/ml, the value for HIV infected without opportunistic infections and
46.4 ± 16.2 nmol/ml, the value for healthy controls (p value < 0.01). The level of HIV/TB coinfected
NO in patients declined to 144.5 ± 34.4 nmol/ml at four weeks of therapy (p value < 0.05). Mean
citrulline among HIV/TB coinfected was 1446.8 ± 468.8 nmol/ml. This was significantly higher than
880.8 ± 434.8 nmol/ml, the value for HIV infected without opportunistic infections and 486.6 ±
212.5 nmol/ml, the value for healthy controls (p value < 0.01). Levels of citrolline in HIV/TB infected
declined to 1116.2 ± 388.6 nmol/ml at four weeks of therapy (p value < 0.05).
Conclusions: NO production is elevated among patients with HIV infection, especially so among
HIV/TB coinfected patients, but declines significantly following 4 weeks of antitubercular therapy.
Background
Nitric oxide (NO) is an free-radical gas and an important
biologically active molecule that participates in host de-
fense against microbes, tumor cells and alloantigens.[1] It
is synthesized from L- arginine by a family of three en-
zyme NO synthase (NOS) proteins, two of which are con-
stitutive (type I and III) and one inducible (type II or
iNOS).[2] Citrulline is released by the above reaction.[3]
NO is readily transformed into nitrite and nitrate which
are excreted into the urine. Type II NOS plays a significant
role in various inflammatory processes and also in the
functioning of the immune system. [4–8]
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Production of NO is elevated among patients with HIV in-
fection. [9–11] These levels may, however, be decreased
among patients with advanced disease.[12] Elevated lev-
els of NO among patients with HIV/TB coinfection have
also been reported. [13–15] The relevance of NO produc-
tion in HIV infection lies in the ability of the former to
modulate the replication of the latter [1,16,17]. Further,
Mycobacterium tuberculosis (Myco. tub.) enhances the
replication of HIV.[18,19] In the presence of elevated NO
production and Myco. tub. infection among HIV infected
the disease tends to progress more rapidly. It is imperative
to treat tuberculosis energetically and remove one of the
variables that affect HIV replication.
Use of antitubercular medications has been shown to re-
duce the level of immune activation in the HIV/TB coin-
fected. [20] There has been one previous study looking at
the level of NO metabolites after chemotherapy in pa-
tients with HIV/TB coinfection.[21] In that study untreat-
ed HIV positive patients with pulmonary TB did not have
increased urinary nitrite/nitrate levels as compared with
controls. As opposed to this HIV negative patients with
pulmonary TB had higher urinary metabolite levels and
when some of them were followed after chemotherapy
there was a significant reduction in these levels.[21] In
view of the conflicting data regarding NO production fol-
lowing chemotherapy among the HIV/TB coinfected, we
carried out this study to determine if NO production, as
measured by its surrogate markers nitrite and citrulline, is
elevated among patients with HIV/TB coinfection and if it
changes following four weeks of anti-tubercular therapy.
Methods
Patients
Nineteen patients with HIV infection who were diagnosed
on the basis of positivity on a panel of three ELISA's and
documented to have active TB as shown by AFB positivity
were included in the study. They were administered an-
titubercular therapy (Rifampicin, INH, Ethambutol and
Pyrazinamide) in doses appropriate for weight. Blood
samples in these cases were taken at the start and at the
end of 4 weeks of therapy, which was continued as per
standard guidelines. Twenty patients with HIV infection
but with no opportunistic infection were studied as dis-
ease controls. The latter was ruled out by absence of clini-
cal features of any opportunistic infection and normal
hemogram, routine biochemical parameters and chest x-
ray. In addition, 20 healthy individuals served as controls.
Nitrite and citrulline measurement
Measurement of NO production in vivo is difficult be-
cause of its short half-life and the need for specialised
equipment that uses chemiluminescence detection. Con-
sequently, nitrite and citrulline levels were used as surro-
gate markers for estimating NO production. Nitrite and
citrulline were measured in the serum by methods de-
scribed previously.[22,23] Samples were stored at -20º C
until analysis. For nitrite estimation, 100 ul of serum was
reacted with 100 ul of Griess reagent (1% sulfanilide (w/
v) in 5% o-phosphoric acid and 0.1% N-1 (napthyl ethyl-
ene diamine dihydrochloride and 2% H3PO4). Absorb-
ance was read at 546 nm. Sodium nitrate (10–100 nmol)
was used as standard. Citrulline was measured in serum
by taking 100 ul of serum, diluting it 20 fold, and depro-
teinizing it using 0.5 ml of 25% tricarboxylic acid solu-
tion. To 0.5 ml of clear supernatant so obtained by
centrifugation, 1.5 ml of chromogenic solution was add-
ed, mixed vigorously and boiled at 1000 C for 5 min. The
tubes were cooled to room temperature and absorbance
was read at 530 nm. DL-citrulline (25–300 nmol) was
used as standard.
Table 1: Clinical profile of patients and disease and healthy controls
Feature HIV+/TB+ HIV+/TB- HIV-/TB-
Number 19 20 20
Males 12 14 15
Age, years 28.4 ± 6.8 26.5±4.6 25.7 ± 3.6
Range 19–48 22–37 21–44
Clinical signs suggesting TB (fever, weight loss, etc) 18 0 0
Radiological abnormality (Chest x-ray/ CT defect) 15 0 0
Disseminated TB 6 0 0
Mean CD4 count, /mm3* 116 ± 36.6 162.4 ± 24.2
Range 14–456 48–440
* Mean CD4 counts of HIV/TB coinfected were significantly lower than those of patients with HIV infection alone (p < 0.05)BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/15
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CD4 counts
To determine CD4+ T cell population, 10 ul of anti-hu-
man CD4-FITC (Sigma Immunochemicals) was added to
100 ul of whole blood and incubated at room tempera-
ture for 15 min. At the end of the incubation, lysing solu-
tion was added and incubated for 10 min at room
temperature. The washed and fixed cells were then ana-
lyzed on the flowcytometer (FACScan, Becton Dickinson,
Mountain View, CA). Ten thousand cells were computed
and analyzed using Cell Quest program. Dead cells were
excluded by forward and side scatter gating. Statistical
markers were set using irrelevant isotype-matched con-
trols as reference.
Statistical analysis
The results in the groups were normally distributed as
shown by Shapiro-Wilk W test and were analyzed by two-
way analysis of variance (ANOVA). Pearson's correlation
coefficient was calculated to determine correlation be-
tween serum level of nitrite and citrulline and CD4
counts. A p value less than 0.05 was considered signifi-
cant.
Results
Clinical profile of the two groups of patients and healthy
individuals is shown in Table 1. The patients were both
out patients and hospitalized ones. They were well
matched for age and sex and none of them had evidence
of renal insufficiency as shown by normal urine examina-
tion and normal blood urea and creatinine values. The
mean CD4 counts of HIV/TB coinfected were significantly
lower than those of patients with HIV infection alone (p <
0.05).
Serum nitrite levels are shown in figures 1 and 2. Mean ni-
trite levels among the HIV/TB coinfected were 207.6 ±
48.8 nmol/ml and in those with HIV infection alone these
were 99.7 ± 26.5 nmol/ml. Healthy controls had mean ni-
trite levels of 46.4 ± 16.2 nmol/ml. The levels among the
HIV/TB coinfected were significantly higher than the other
two groups (p < 0.01). Levels among patients with HIV in-
fection alone were significantly higher than those of
healthy controls (p < 0.05). Following 4 weeks of chemo-
therapy nitrite levels declined to 144.5 ± 34.4 nmol/ml
among the HIV/TB coinfected. These were significantly
lower than at start of therapy (p < 0.05). There was no cor-
relation between CD4 counts and nitrite levels.
Serum citrulline levels are shown in figures 3 and 4. Mean
serum citrulline levels in the HIV/TB coinfected were
1446.8 ± 468.8 nmol/ml and those with HIV infection
alone were 880.8 ± 434.8 nmol/ml. Healthy controls had
levels of 486.6 ± 212.5 nmol/ml. Levels among HIV/TB
coinfected were significantly higher than the other two
groups (p < 0.01) and those with HIV infection alone had
significantly higher levels than controls (p < 0.05). Thera-
py for TB among the HIV/TB coinfected for 4 weeks result-
ed in a significant decline to 1116.2 ± 388.6 nmol/ml (p
< 0.05). There was no correlation between CD4 counts
and citrulline levels.
Discussion
Our results showing that NO production is elevated
among patients with HIV infection and still higher in
those with coinfection with TB suggest a role for NO
Figure 1
Mean nitrite levels among the HIV/TB coinfected, those with
HIV infection alone and healthy controls were 207.6 ± 48.8
nmol/ml, 99.7 ± 26.5 nmol/ml and 46.4 ± 16.2 nmol/ml,
respectively. Levels among the HIV/TB coinfected were sig-
nificantly higher than the other two groups (p < 0.01) and
those among patients with HIV infection alone were signifi-
cantly higher than those of healthy controls (p < 0.05).
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Figure 2
Four weeks of chemotherapy led to decline of nitrite levels
from 207.6 ± 48.8 nmol/ml to 144.5 ± 34.4 nmol/ml among
the HIV/TB coinfected. These were significantly lower than at
start of therapy (p < 0.05).
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among these individuals. Further, we have demonstrated
a decline in NO production among the HIV/TB coinfected
following four weeks of antitubercular therapy.
NO has been shown to modulate several immune func-
tions.[24,25] There have, however, been some contrasting
effects attributed to NO. It upregulates proliferation and
increases glucose uptake by T lymphocytes, while other re-
ports have suggested that it inhibits T cell activa-
tion.[26,27] HIV infected patients are known to have
elevated levels of proinflammatory cytokines, especially
tumor necrosis factor (TNF)-α .[11] These are powerful ac-
tivators of HIV replication.[28] Cytokines produced in re-
sponse to cell activation can to stimulate iNOS in a
autocrine or paracrine manner.
The significance of NO production in HIV infection has
been well established. There is an accumulation of NO
metabolites, nitrite and nitrate, in individuals who have
neurological complications.[29] Nitrite and citrulline lev-
els are elevated among those HIV infected individuals
who have no opportunistic infection.[11] There is also ev-
idence to show an association between high levels of virus
load and increase NO production in the serum of HIV in-
fected patients.[30] Consequently, production of large
amounts of NO by macrophages could be a leading cause
of lymphocyte inactivation and induction of persistent
immunosuppression.[31]
Evidence for the role of iNOS in TB comes from several
studies. NO has been demonstrated to kill 99% Myco.
tub. in culture in two days at a concentration of 90
ppm.[32] iNOS inhibitors exacerbate infection in macro-
phages and mice treated during acute or chronic phase of
disease.[33] Myco tub grows rapidly and kills mice that
have been rendered selectively deficient in iNOS.[34]
Elevated levels of NO in HIV infection may be due to cy-
tokines, mainly TNF-α  and interleukin-6.[35] Both these
cytokines play an important role in TB too as NO levels
may be stimulated directly by Myco. tub.[36] It is likely
that there is some cumulative effect of the increase and,
hence, it is easy to see why NO levels are still higher in in-
dividuals with the coinfection as demonstrated in this
study. It is pertinent to note that NO is involved in HIV-1
replication, especially that induced by TNF-α .[1] There
might, therefore, be a self perpetuating mechanism where-
in HIV replication leads to increased NO production and
the latter increases the rate of HIV multiplication.
Effect of four weeks of therapy in reducing NO production
is significant in view of the fact that this coincides with the
onset of clinical response. There is reduced immune acti-
vation at that time.[20] There are significant clinical im-
plications of this for therapy. Thus, while chemotherapy
cures Myco. tub. infection in immunocompetent mice it
fails to do so in iNOS-deficient mice.[38] Further, some
commonly used drugs that are tuberculocidal in vitro are
comparably effective in vivo only with the help of
iNOS.[38] In effect chemotherapy might be more benefi-
cial to immunocompromised hosts if accompanied by de-
livery of a source of NO. Sensitization of tubercle bacilli
to NO might reduce the time for chemotherapeutic bene-
Figure 3
Mean serum citrulline levels in the HIV/TB coinfected, those
with HIV infection alone and healthy controls were 1446.8 ±
468.8 nmol/ml, 880.8 ± 434.8 nmol/ml and 486.6 ± 212.5
nmol/ml, respectively. Levels among HIV/TB coinfected were
significantly higher than the other two groups (p < 0.01) and
those with HIV infection alone had significantly higher levels
than controls (p < 0.05).
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Figure 4
Therapy for TB among the HIV/TB coinfected for 4 weeks
resulted in a significant decline from 1446.8 ± 468.8 nmol/ml
to 1116.2 ± 388.6 nmol/ml (p < 0.05).
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fit in immunocompetent hosts and might bring down the
incidence of treatment interruption and consequent drug
resistance. Since all the patients in the study received ri-
fampicin, the role of the latter as an anti-inflammatory
agent needs some consideration. Rifampicin activates the
human glucocorticoid receptor.[39] Transient expression
of wild-type, deleted or mutated glucocorticoid receptors
and sucrose density gradient sedimentation studies have
suggested that the drug binds to the receptor with the
physiological consequence that this antibiotic acts as an
immunosuppressive agent.[39] Four weeks can produce
an anti-inflammatory effect to be produced enough to re-
duce the level of immune activation reflecting in a de-
crease in NO production. This is likely to have been
abetted by a decrease in the level of immune activation
due to a decrease in bacillary load and antigenic stimula-
tion.
In conclusion, we have demonstrated that NO production
is elevated among patients with HIV infection and is still
higher in those with coinfection with TB and that these
levels decline with four weeks of anti-tubercular therapy.
Taken along with other studies mentioned previously
there may be a case to suggest that NO plays a deleterious
role in HIV infection. It would be interesting to see what
effect NOS inhibitors might produce if combined with
standard antitubercular therapy in HIV/TB coinfected.
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